Latest news with #ECLIPSE
RNZ News
20 hours ago
- General
- RNZ News
How Debbs Murray found freedom and safety
Debbs Murray has spent more than two decades working tirelessly in the family violence sector, for refuge, and various government and non-government agencies including the police. She is the founder of ECLIPSE family violence services based in Waikato, through which thousands of frontline family harm prevention workers have been trained. The training focusses on helping practitioners build greater understanding of the complexity of family violence and coercive control - and why so many victims don't or can't get out. But through all of that advocacy over 20 years, Debbs has never really shared her own experience in writing, of the seven years she was in a relationship marked by severe family violence and absolute coercive control. She's now written a book about her extraordinary journey - and that of her four children. It's aimed at anyone experiencing family violence and their loved ones who want to help. Photo: supplied
Yahoo
02-06-2025
- Business
- Yahoo
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening
First national guideline recommendation for Shield paves the way for improved patient access and additional major guideline inclusions NCCN guidelines point to landmark ECLIPSE Study showing efficacy of Shield Shield is FDA-approved for adults age 45 or older at average risk for colorectal cancer PALO ALTO, Calif., June 02, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the National Comprehensive Cancer Network (NCCN) has included the Shield blood test in its updated colorectal cancer (CRC) screening guidelines. The Shield test detects CRC signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA). The updated NCCN CRC Screening Guidelines reflect the addition of Shield with a recommendation for testing every three years. "With a simple blood draw, Shield provides a more convenient and pleasant screening option for the millions of eligible Americans who are forgoing their recommended screening for colorectal cancer," said AmirAli Talasaz, Guardant Health co-CEO. "This major guideline inclusion from the National Comprehensive Cancer Network is just the first for Shield, and we believe a pivotal step for more patients to benefit from this test." In its guideline update, the NCCN pointed to Guardant's landmark ECLIPSE (Evaluation of ctDNA LUNAR Assay in an Average Patient Screening Episode) study evaluating the performance of Shield compared to a screening colonoscopy. One of the largest studies of its kind and published in the New England Journal of Medicine (NEJM), ECLIPSE demonstrated that the Shield blood test is highly effective in detecting CRC, with a sensitivity of 83 percent. About Shield Shield is a non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Meaghan Smithpress@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
02-06-2025
- Health
- Business Wire
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the National Comprehensive Cancer Network (NCCN) has included the Shield blood test in its updated colorectal cancer (CRC) screening guidelines. The Shield test detects CRC signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA). The updated NCCN CRC Screening Guidelines reflect the addition of Shield with a recommendation for testing every three years. 'With a simple blood draw, Shield provides a more convenient and pleasant screening option for the millions of eligible Americans who are forgoing their recommended screening for colorectal cancer,' said AmirAli Talasaz, Guardant Health co-CEO. 'This major guideline inclusion from the National Comprehensive Cancer Network is just the first for Shield, and we believe a pivotal step for more patients to benefit from this test.' In its guideline update, the NCCN pointed to Guardant's landmark ECLIPSE (Evaluation of ctDNA LUNAR Assay in an Average Patient Screening Episode) study evaluating the performance of Shield compared to a screening colonoscopy. One of the largest studies of its kind and published in the New England Journal of Medicine (NEJM), ECLIPSE demonstrated that the Shield blood test is highly effective in detecting CRC, with a sensitivity of 83 percent. About Shield Shield is a non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
7NEWS
26-05-2025
- Entertainment
- 7NEWS
Best-selling Aussie fine jewellery brand taking over Hollywood A-list and you can own the same pieces
When it comes to jewellery that screams quiet luxury with just the right amount of edge, ALINKA Fine Jewellery might just be the fashion world's best-kept secret, until now. Worn by Taylor Swift, Natalie Portman, Dua Lipa, Vanessa Kirby, Miranda Kerr and Alicia Vikander, this Sydney-born label is quietly taking over red carpets, magazine covers and curated earring stacks everywhere. And once you see the pieces, it's not hard to understand why. Founded by designer Alina Barlow in 2015, ALINKA is all about refined rebellion. Each piece is designed with versatility in mind, elegant enough to wear to a black-tie event, but with that sculptural twist that makes it feel modern, wearable and just a bit daring. Think sleek curves, monochrome sparkle, and diamonds where you least expect them. Let's talk about Taylor Swift, because obviously. The global superstar stepped out in ALINKA's ECLIPSE and KATIA rings following the BAFTA Awards in 2019, giving Swifties (and fashion editors alike) a reason to zoom in on every paparazzi shot. Natalie Portman wore the Katia Ear Cuff for Vogue, while Dua Lipa showcased a stunning Black Diamond Drop Earring and ring combo in her Vogue Australia editorial. Miranda Kerr graced the cover of Harper's Bazaar in full ALINKA sparkle. We're talking serious celebrity approval, but without the usual 'only if you're an A-lister' price tag. The jewellery itself is handcrafted in 18K gold, your pick of white, yellow or rose, and uses high-quality black and white diamonds to create contrast and dimension. Founder Alina Barlow is known for her love of minimalist monochrome, but each design still brings the drama. Ready to shop like an A-lister? Here are 7 standout pieces stealing the Hollywood spotlight: ALINKA LINKA Mini Hoop Earrings, $1,600 each ALINKA Dasha Ear Cuff, $3,900 ALINKA ECLIPSE Ring, $2,700 ALINKA KATIA Ear Cuff, $1,500 ALINKA LINKA Grande Hoop Earrings, $11,900 ALINKA STASIA MINI Pink Sapphire Stud Earring Single, $650 ALINKA STASIA Star Mini Diamond Necklace, $1,500 Nothing brings the drama quite like creating ALINKA's viral LINKA earring stack. The LINKA Grande and LINKA Mini earrings are sculptural hoops with diamonds encrusted on the inside back, meaning they sparkle even when seen from behind. Genius. Add ALINKA's NATALIA DOUBLE Diamond Stud Earring Single to complete your stack. Whether you're a fan of stacking or prefer one standout piece, the beauty of ALINKA is in its mix-and-match potential. And yes, these pieces are an investment, but unlike fast fashion jewellery that tarnishes after a few wears, ALINKA is made to last and be worn. As Alina Barlow puts it, 'A perfect balance of elegance and innovation.' We couldn't agree more.
Yahoo
14-03-2025
- Health
- Yahoo
Vir enrols first subject in Phase III programme to assess CHD therapy
Vir Biotechnology has enrolled the first subject in the Phase III ECLIPSE registrational programme of tobevibart and elebsiran in individuals with chronic hepatitis delta (CHD), an inflammatory liver condition. The programme is designed to assess the safety and efficacy of the combination in this patient population. It includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer the registrational data required for regulatory submissions. The Phase IIb ECLIPSE 3 trial seeks to support access and reimbursement strategies in the European markets. ECLIPSE 1 aims to enrol 120 subjects across the US and other select regions, comparing the combination therapy to deferred treatment. Subjects will be randomised to receive either the combination or deferred treatment. Measuring HDV RNA and serum alanine aminotransferase normalisation at week 48 will be the trial's primary endpoint. ECLIPSE 2 focuses on subjects who have not obtained viral suppression with bulevirtide treatment, while ECLIPSE 3, the head-to-head trial, will evaluate the combination with bulevirtide in treatment-naïve individuals. CHD is said to occur due to the hepatitis delta virus (HDV), leading to cirrhosis and liver failure within five years for many people affected. Vir Biotechnology CEO Marianne De Backer said: 'The start of the ECLIPSE programme marks a pivotal moment for patients living with hepatitis delta and for Vir Biotechnology. 'With a proven track record of developing treatments powering the immune system to transform lives, this achievement is a testament to our ability to rapidly advance impactful treatments from discovery to patient care.' Tobevibart, a monoclonal antibody, and elebsiran, a small interfering ribonucleic acid, are the investigational candidates that were discovered by Vir Biotechnology and Alnylam Pharmaceuticals, respectively. The combination therapy received breakthrough and fast track designation from the US Food and Drug Administration, as well as orphan drug and priority medicines status from the European Medicines Agency. In September 2023, Vir dosed the first subject in the Phase I HVTN 142 trial of VIR-1388, a T-cell vaccine candidate aimed at preventing human immunodeficiency virus. "Vir enrols first subject in Phase III programme to assess CHD therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
